

# Stefan M Pfister

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5003998/publications.pdf>

Version: 2024-02-01

594  
papers

81,593  
citations

630

127  
h-index

679

262  
g-index

625  
all docs

625  
docs citations

625  
times ranked

67337  
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	13.7	8,060
2	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. <i>Neuro-Oncology</i> , 2021, 23, 1231-1251.	0.6	4,534
3	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.	13.7	2,129
4	International network of cancer genome projects. <i>Nature</i> , 2010, 464, 993-998.	13.7	2,114
5	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	13.7	1,966
6	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	13.7	1,872
7	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	7.7	1,551
8	Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , 2012, 123, 465-472.	3.9	1,536
9	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	0.8	1,131
10	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	13.7	1,068
11	Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process. <i>PLoS ONE</i> , 2008, 3, e2213.	1.1	939
12	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	7.7	933
13	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 397-405.	3.9	914
14	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	3.9	863
15	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. <i>Acta Neuropathologica</i> , 2012, 124, 439-447.	3.9	799
16	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	13.7	787
17	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	13.7	765
18	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	13.7	761

#	ARTICLE	IF	CITATIONS
19	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	13.5	743
20	Glioma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15017.	18.1	718
21	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. <i>Cancer Cell</i> , 2017, 32, 520-537.e5.	7.7	716
22	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	13.5	702
23	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <i>Nature</i> , 2012, 488, 106-110.	13.7	675
24	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	9.4	674
25	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. <i>Cancer Cell</i> , 2013, 24, 660-672.	7.7	633
26	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627
27	Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. <i>Lancet Oncology</i> , The, 2020, 21, 531-540.	5.1	608
28	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	5.1	586
29	Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , 2012, 12, 818-834.	12.8	560
30	Challenges to curing primary brain tumours. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 509-520.	12.5	540
31	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	13.7	521
32	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	13.7	520
33	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	7.7	494
34	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	3.9	478
35	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. <i>Nature Reviews Cancer</i> , 2014, 14, 92-107.	12.8	469
36	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	7.7	438

#	ARTICLE	IF	CITATIONS
37	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. <i>Journal of Clinical Investigation</i> , 2008, 118, 1739-1749.	3.9	437
38	BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1. <i>Nature Medicine</i> , 2013, 19, 901-908.	15.2	388
39	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	0.8	381
40	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.	9.4	381
41	DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. <i>Aging Cell</i> , 2010, 9, 54-63.	3.0	378
42	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <i>Nature</i> , 2014, 510, 537-541.	13.7	378
43	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	3.9	378
44	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. <i>Acta Neuropathologica</i> , 2012, 124, 615-625.	3.9	376
45	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	13.7	376
46	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	18.1	376
47	Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. <i>Nature Reviews Genetics</i> , 2013, 14, 765-780.	7.7	373
48	Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, e38-e45.	3.2	358
49	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	13.5	348
50	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. <i>Nature Genetics</i> , 2017, 49, 65-74.	9.4	326
51	Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2-STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. <i>Acta Neuropathologica</i> , 2013, 125, 651-658.	3.9	324
52	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. <i>Acta Neuropathologica</i> , 2012, 123, 615-626.	3.9	318
53	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	13.7	318
54	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. <i>Lancet Oncology</i> , 2019, 20, 1011-1022.	5.1	315

#	ARTICLE	IF	CITATIONS
55	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210.	3.9	308
56	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	5.1	307
57	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	3.9	298
58	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	3.9	277
59	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the <i>MYC</i> and <i>MYCN</i> Loci. <i>Journal of Clinical Oncology</i> , 2009, 27, 1627-1636.	0.8	274
60	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	5.1	274
61	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	13.7	273
62	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	3.9	271
63	Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. <i>Acta Neuropathologica</i> , 2014, 128, 551-559.	3.9	268
64	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	5.1	268
65	An Animal Model of MYC-Driven Medulloblastoma. <i>Cancer Cell</i> , 2012, 21, 155-167.	7.7	267
66	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. <i>Nature Communications</i> , 2015, 6, 10001.	5.8	266
67	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	13.7	266
68	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	0.8	263
69	Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study. <i>European Journal of Cancer</i> , 2016, 65, 91-101.	1.3	262
70	The clinical implications of medulloblastoma subgroups. <i>Nature Reviews Neurology</i> , 2012, 8, 340-351.	4.9	261
71	Low physiologic oxygen tensions reduce proliferation and differentiation of human multipotent mesenchymal stromal cells. <i>BMC Cell Biology</i> , 2010, 11, 11.	3.0	260
72	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. <i>Acta Neuropathologica</i> , 2009, 118, 401-405.	3.9	255

#	ARTICLE	IF	CITATIONS
73	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	3.9	254
74	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. <i>Acta Neuropathologica</i> , 2013, 125, 659-669.	3.9	250
75	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
76	Mutations in the SIX1/2 Pathway and the DROSHA/DGCR8 miRNA Microprocessor Complex Underlie High-Risk Blastemal Type Wilms Tumors. <i>Cancer Cell</i> , 2015, 27, 298-311.	7.7	248
77	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	3.9	244
78	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. <i>Nature Communications</i> , 2015, 6, 7391.	5.8	244
79	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 33-47.	7.7	241
80	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015, 130, 407-417.	3.9	237
81	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	5.8	237
82	Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	3.6	236
83	BAF complexes facilitate decatenation of DNA by topoisomerase II±. <i>Nature</i> , 2013, 497, 624-627.	13.7	230
84	Pediatric Gliomas: Current Concepts on Diagnosis, Biology, and Clinical Management. <i>Journal of Clinical Oncology</i> , 2017, 35, 2370-2377.	0.8	223
85	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
86	Adult Medulloblastoma Comprises Three Major Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 2717-2723.	0.8	215
87	Identification of Gains on 1q and Epidermal Growth Factor Receptor Overexpression as Independent Prognostic Markers in Intracranial Ependymoma. <i>Clinical Cancer Research</i> , 2006, 12, 2070-2079.	3.2	212
88	Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. <i>Lancet Oncology</i> , 2013, 14, 534-542.	5.1	212
89	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774.	3.9	211
90	Molecular Staging of Intracranial Ependymoma in Children and Adults. <i>Journal of Clinical Oncology</i> , 2010, 28, 3182-3190.	0.8	210

#	ARTICLE	IF	CITATIONS
91	Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations. <i>Acta Neuropathologica</i> , 2013, 125, 351-358.	3.9	208
92	HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma. <i>Cancer Cell</i> , 2016, 29, 311-323.	7.7	204
93	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	3.9	203
94	Childhood cancer predisposition syndromesâ€”A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. <i>American Journal of Medical Genetics, Part A</i> , 2017, 173, 1017-1037.	0.7	200
95	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , 2018, 136, 211-226.	3.9	199
96	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	3.9	195
97	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 793-803.	3.9	195
98	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	3.9	191
99	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291.	3.9	190
100	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. <i>Nature Medicine</i> , 2016, 22, 1314-1320.	15.2	183
101	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	3.9	180
102	MAPK pathway activation in pilocytic astrocytoma. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1799-1811.	2.4	177
103	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	3.9	176
104	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252.	3.2	175
105	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1408-1416.	0.6	175
106	EANO guidelines for the diagnosis and treatment of ependymal tumors. <i>Neuro-Oncology</i> , 2018, 20, 445-456.	0.6	173
107	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. <i>Nature Medicine</i> , 2020, 26, 712-719.	15.2	172
108	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	13.7	170

#	ARTICLE	IF	CITATIONS
109	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 848-857.	0.6	170
110	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation. <i>Acta Neuropathologica</i> , 2019, 137, 683-687.	3.9	170
111	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	3.9	169
112	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017, 134, 705-714.	3.9	168
113	Molecular neuro-oncology in clinical practice: a new horizon. <i>Lancet Oncology</i> , The, 2013, 14, e370-e379.	5.1	167
114	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. <i>Acta Neuropathologica</i> , 2016, 131, 137-146.	3.9	162
115	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	0.8	160
116	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	7.7	157
117	Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma. <i>Acta Neuropathologica</i> , 2017, 133, 431-444.	3.9	155
118	Methylation-based classification of benign and malignant peripheral nerve sheath tumors. <i>Acta Neuropathologica</i> , 2016, 131, 877-887.	3.9	151
119	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	5.1	151
120	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. <i>Lancet Oncology</i> , The, 2012, 13, 838-848.	5.1	148
121	Medulloblastomics revisited: biological and clinical insights from thousands of patients. <i>Nature Reviews Cancer</i> , 2020, 20, 42-56.	12.8	147
122	The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. <i>International Journal of Cancer</i> , 2008, 122, 1207-1213.	2.3	146
123	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	3.9	146
124	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2018, 34, 396-410.e8.	7.7	146
125	Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 539-552.	3.9	145
126	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	3.9	144



#	ARTICLE	IF	CITATIONS
127	<i>FSTL5</i> Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	0.8	143
128	Molecular subgroups of medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 871-884.	1.4	142
129	Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial. <i>Cancer Cell</i> , 2018, 33, 829-842.e5.	7.7	140
130	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. <i>Journal of Clinical Oncology</i> , 2010, 28, 3054-3060.	0.8	136
131	Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. <i>Acta Neuropathologica Communications</i> , 2016, 4, 20.	2.4	136
132	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. <i>Clinical Cancer Research</i> , 2011, 17, 4650-4660.	3.2	135
133	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. <i>Acta Neuropathologica</i> , 2010, 120, 253-260.	3.9	129
134	Recurrent noncoding U1 snRNA mutations drive cryptic splicing in SHH medulloblastoma. <i>Nature</i> , 2019, 574, 707-711.	13.7	129
135	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. <i>Acta Neuropathologica</i> , 2016, 132, 149-151.	3.9	127
136	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. <i>Acta Neuropathologica</i> , 2014, 128, 137-149.	3.9	125
137	Molecular Insights into Pediatric Brain Tumors Have the Potential to Transform Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5630-5640.	3.2	124
138	A biobank of patient-derived pediatric brain tumor models. <i>Nature Medicine</i> , 2018, 24, 1752-1761.	15.2	124
139	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. <i>Clinical Cancer Research</i> , 2017, 23, e83-e90.	3.2	122
140	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. <i>Journal of Clinical Oncology</i> , 2016, 34, 4151-4160.	0.8	121
141	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017, 133, 1-3.	3.9	120
142	A cell-based model system links chromothripsis with hyperploidy. <i>Molecular Systems Biology</i> , 2015, 11, 828.	3.2	118
143	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. <i>Nature Communications</i> , 2017, 8, 14758.	5.8	118
144	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	3.9	118

#	ARTICLE	IF	CITATIONS
145	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. <i>Acta Neuropathologica</i> , 2014, 128, 733-741.	3.9	116
146	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	0.6	116
147	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	3.9	116
148	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). <i>Acta Neuropathologica</i> , 2012, 124, 875-881.	3.9	115
149	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	9.4	112
150	HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. <i>Journal of Neuro-Oncology</i> , 2012, 110, 335-348.	1.4	110
151	The G protein $\alpha$ subunit $G\alpha$ is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. <i>Nature Medicine</i> , 2014, 20, 1035-1042.	15.2	110
152	The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets. <i>Cancer Discovery</i> , 2021, 11, 2764-2779.	7.7	110
153	Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. <i>Acta Neuropathologica</i> , 2009, 117, 457-464.	3.9	106
154	EZH1/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 878-889.	0.6	106
155	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	0.8	106
156	High-resolution genomic profiling of childhood T-ALL reveals frequent copy-number alterations affecting the TGF- $\beta$ and PI3K-AKT pathways and deletions at 6q15-16.1 as a genomic marker for unfavorable early treatment response. <i>Blood</i> , 2009, 114, 1053-1062.	0.6	105
157	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. <i>Cancer Cell</i> , 2018, 34, 379-395.e7.	7.7	104
158	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	3.9	104
159	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	3.9	104
160	Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation. <i>Acta Neuropathologica</i> , 2020, 139, 1109-1113.	3.9	104
161	Nuclear relocation of STAT6 reliably predicts NAB2-STAT6 fusion for the diagnosis of solitary fibrous tumour. <i>Histopathology</i> , 2014, 65, 613-622.	1.6	101
162	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. <i>Acta Neuropathologica Communications</i> , 2019, 7, 24.	2.4	101

#	ARTICLE	IF	CITATIONS
163	<i>TP53</i> Mutation Is Frequently Associated With <i>CTNNB1</i> Mutation or <i>MYCN</i> Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5188-5196.	0.8	100
164	N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 95-105.	0.6	100
165	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. <i>Nature Reviews Cancer</i> , 2019, 19, 420-438.	12.8	98
166	CD28 Signaling via VAV/SLP-76 Adaptors. <i>Immunity</i> , 2001, 15, 921-933.	6.6	96
167	Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions. <i>Nucleic Acids Research</i> , 2015, 43, e10-e10.	6.5	95
168	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	13.7	94
169	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. <i>Cancer Cell</i> , 2020, 38, 44-59.e9.	7.7	94
170	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	13.7	94
171	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	13.5	93
172	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	0.8	93
173	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. <i>Cancer Research</i> , 2017, 77, e62-e66.	0.4	92
174	MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin. <i>Cancer Cell</i> , 2015, 28, 715-729.	7.7	90
175	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662.	2.1	89
176	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. <i>Nature Protocols</i> , 2020, 15, 479-512.	5.5	89
177	AKT1E17K mutations cluster with meningotheial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry. <i>Acta Neuropathologica</i> , 2013, 126, 757-762.	3.9	88
178	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 501-513.	3.9	87
179	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
180	A Tumor Suppressor Function for Notch Signaling in Forebrain Tumor Subtypes. <i>Cancer Cell</i> , 2015, 28, 730-742.	7.7	85

#	ARTICLE	IF	CITATIONS
181	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2013, 126, 291-301.	3.9	84
182	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. <i>Clinical Cancer Research</i> , 2015, 21, 184-192.	3.2	84
183	Molecular diagnostics of CNS embryonal tumors. <i>Acta Neuropathologica</i> , 2010, 120, 553-566.	3.9	83
184	Integrative Genome-Scale Analysis Identifies Epigenetic Mechanisms of Transcriptional Deregulation in Unfavorable Neuroblastomas. <i>Cancer Research</i> , 2016, 76, 5523-5537.	0.4	83
185	Transcriptomic and epigenetic profiling of diffuse midline gliomas, H3 K27M-mutant™ discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. <i>Acta Neuropathologica Communications</i> , 2018, 6, 117.	2.4	83
186	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	3.9	83
187	Medulloblastoma subgroups remain stable across primary and metastatic compartments. <i>Acta Neuropathologica</i> , 2015, 129, 449-457.	3.9	80
188	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018, 20, 367-379.	0.6	79
189	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. <i>Acta Neuropathologica</i> , 2011, 122, 637-650.	3.9	77
190	Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. <i>Neuro-Oncology</i> , 2014, 16, 1630-1638.	0.6	77
191	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 839-851.	1.5	76
192	Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information. <i>Modern Pathology</i> , 2018, 31, 1246-1256.	2.9	76
193	Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. <i>International Journal of Cancer</i> , 2011, 129, 2297-2303.	2.3	75
194	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. <i>Neuro-Oncology</i> , 2021, 23, 34-43.	0.6	75
195	Coverage Bias and Sensitivity of Variant Calling for Four Whole-genome Sequencing Technologies. <i>PLoS ONE</i> , 2013, 8, e66621.	1.1	74
196	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. <i>Acta Neuropathologica</i> , 2015, 130, 419-434.	3.9	74
197	Gliomatosis cerebri: no evidence for a separate brain tumor entity. <i>Acta Neuropathologica</i> , 2016, 131, 309-319.	3.9	74
198	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	2.9	74

#	ARTICLE	IF	CITATIONS
199	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308.	3.9	74
200	The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. <i>American Journal of Pathology</i> , 2012, 181, 1762-1772.	1.9	73
201	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. <i>Neuro-Oncology</i> , 2013, 15, 1644-1651.	0.6	73
202	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
203	Evidence of H3 K27M mutations in posterior fossa ependymomas. <i>Acta Neuropathologica</i> , 2016, 132, 635-637.	3.9	73
204	Super enhancers define regulatory subtypes and cell identity in neuroblastoma. <i>Nature Cancer</i> , 2021, 2, 114-128.	5.7	73
205	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. <i>Lancet Oncology</i> , The, 2015, 16, e293-e302.	5.1	72
206	Recurrent intragenic rearrangements of EGFR and BRAF in soft tissue tumors of infants. <i>Nature Communications</i> , 2018, 9, 2378.	5.8	72
207	Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem. <i>Acta Neuropathologica</i> , 2012, 123, 601-614.	3.9	71
208	Adaptor FYB (Fyn-binding protein) regulates integrin-mediated adhesion and mediator release: Differential involvement of the FYB SH3 domain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 11527-11532.	3.3	70
209	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era. <i>Cancer Discovery</i> , 2022, 12, 331-355.	7.7	70
210	The Genetics of Pediatric Brain Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 215-223.	2.0	69
211	Integrated molecular characterization of IDH <sup>mutant</sup> glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118.	1.8	68
212	Response to trametinib treatment in progressive pediatric low-grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2020, 149, 499-510.	1.4	68
213	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 1344-1348.	3.9	68
214	Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. <i>Neuro-Oncology</i> , 2011, 13, 866-879.	0.6	67
215	Hypermethylation of the Inactive X Chromosome Is a Frequent Event in Cancer. <i>Cell</i> , 2013, 155, 567-581.	13.5	67
216	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	0.6	67

#	ARTICLE	IF	CITATIONS
217	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	3.9	66
218	Melanotic Tumors of the Nervous System are Characterized by Distinct Mutational, Chromosomal and Epigenomic Profiles. <i>Brain Pathology</i> , 2015, 25, 202-208.	2.1	66
219	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 22.	2.4	66
220	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. <i>Nature Communications</i> , 2018, 9, 4760.	5.8	66
221	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	0.6	65
222	DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment. <i>Neuro-Oncology</i> , 2018, 20, 1616-1624.	0.6	65
223	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3914.	5.8	65
224	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	7.7	65
225	Secretion of angiogenic proteins by human multipotent mesenchymal stromal cells and their clinical potential in the treatment of avascular osteonecrosis. <i>Leukemia</i> , 2008, 22, 2054-2061.	3.3	63
226	cIMPACT@NOW (the consortium to inform molecular and practical approaches to CNS tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 27, 851-852.	2.1	63
227	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.4	62
228	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. <i>Oncotarget</i> , 2016, 7, 28169-28182.	0.8	62
229	Early phase clinical trials of anticancer agents in children and adolescents â€” an ITCC perspective. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 497-507.	12.5	61
230	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 529-538.	3.9	60
231	DNA methylation-based reclassification of olfactory neuroblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 255-271.	3.9	59
232	Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. <i>Nucleic Acids Research</i> , 2007, 35, e51.	6.5	58
233	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	3.5	58
234	Implementation of mechanism of action biology-driven early drug development for children with cancer. <i>European Journal of Cancer</i> , 2016, 62, 124-131.	1.3	58

#	ARTICLE	IF	CITATIONS
235	Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-ependymoid tumor with favorable long-term outcome. <i>Brain Pathology</i> , 2017, 27, 411-418.	2.1	58
236	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	0.8	58
237	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	0.8	58
238	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. <i>Acta Neuropathologica</i> , 2019, 138, 497-504.	3.9	57
239	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). <i>Neuro-Oncology</i> , 2018, 20, 400-410.	0.6	56
240	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. <i>Acta Neuropathologica</i> , 2018, 136, 293-302.	3.9	56
241	Engineering Genetic Predisposition in Human Neuroepithelial Stem Cells Recapitulates Medulloblastoma Tumorigenesis. <i>Cell Stem Cell</i> , 2019, 25, 433-446.e7.	5.2	56
242	TelomereHunter – in silico estimation of telomere content and composition from cancer genomes. <i>BMC Bioinformatics</i> , 2019, 20, 272.	1.2	56
243	EANO – EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. <i>Lancet Oncology</i> , The, 2019, 20, e715-e728.	5.1	56
244	H3.3-K27M drives neural stem cell-specific gliomagenesis in a human iPSC-derived model. <i>Cancer Cell</i> , 2021, 39, 407-422.e13.	7.7	56
245	Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. <i>Nature Communications</i> , 2019, 10, 332.	5.8	55
246	Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging. <i>Brain Pathology</i> , 2019, 29, 325-335.	2.1	55
247	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	3.2	55
248	DNA methylation-based profiling for paediatric CNS tumour diagnosis and treatment: a population-based study. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 121-130.	2.7	55
249	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. <i>Acta Neuropathologica</i> , 2014, 128, 123-136.	3.9	54
250	Recurrent homozygous deletion of DROSHA and microduplication of PDE4DIP in pineoblastoma. <i>Nature Communications</i> , 2018, 9, 2868.	5.8	54
251	Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. <i>Acta Neuropathologica</i> , 2014, 127, 931-933.	3.9	53
252	Molecular mechanisms and therapeutic targets in pediatric brain tumors. <i>Science Signaling</i> , 2017, 10, .	1.6	53

#	ARTICLE	IF	CITATIONS
253	Itch/Î2-arrestin2-dependent non-proteolytic ubiquitylation of SuFu controls Hedgehog signalling and medulloblastoma tumorigenesis. <i>Nature Communications</i> , 2018, 9, 976.	5.8	53
254	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	3.9	52
255	Histology and Molecular Pathology of Pediatric Brain Tumors. <i>Journal of Child Neurology</i> , 2009, 24, 1375-1386.	0.7	51
256	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. <i>Cancer Research</i> , 2015, 75, 134-146.	0.4	51
257	Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases. <i>Clinical Sarcoma Research</i> , 2017, 7, 9.	2.3	51
258	Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience. <i>European Journal of Cancer</i> , 2019, 114, 27-35.	1.3	51
259	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2019, 137, 521-525.	3.9	51
260	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 422-430.	1.8	51
261	Developmental and evolutionary dynamics of cis-regulatory elements in mouse cerebellar cells. <i>Science</i> , 2021, 373, .	6.0	51
262	DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1273-1281.	1.2	50
263	Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-50.	0.8	50
264	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. <i>Acta Neuropathologica</i> , 2020, 139, 243-257.	3.9	50
265	Overcoming multiple drug resistance mechanisms in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 57.	2.4	49
266	Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotype. <i>Clinical Sarcoma Research</i> , 2019, 9, 2.	2.3	48
267	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. <i>Leukemia</i> , 2017, 31, 2048-2056.	3.3	47
268	ETMR: a tumor entity in its infancy. <i>Acta Neuropathologica</i> , 2020, 140, 249-266.	3.9	47
269	Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect <i>Wnt</i> activated tumours. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 135-144.	1.8	46
270	Alternative lengthening of telomeres in childhood neuroblastoma from genome to proteome. <i>Nature Communications</i> , 2021, 12, 1269.	5.8	46



#	ARTICLE	IF	CITATIONS
271	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	0.6	46
272	ZFTAâ€“RELA Dictates Oncogenic Transcriptional Programs to Drive Aggressive Supratentorial Ependymoma. <i>Cancer Discovery</i> , 2021, 11, 2200-2215.	7.7	46
273	Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics. <i>Neuroscience</i> , 2014, 264, 171-185.	1.1	45
274	From class waivers to precision medicine in paediatric oncology. <i>Lancet Oncology</i> , The, 2017, 18, e394-e404.	5.1	45
275	YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218.	3.9	45
276	Infratentorial IDH-mutant astrocytoma is a distinct subtype. <i>Acta Neuropathologica</i> , 2020, 140, 569-581.	3.9	45
277	No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3. <i>Klinische Padiatrie</i> , 2016, 228, 113-117.	0.2	44
278	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44
279	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	3.9	44
280	Moyamoya-like vasculopathy (moyamoya syndrome) in children. <i>Child's Nervous System</i> , 2004, 20, 382-391.	0.6	43
281	Hedgehog-mediated regulation of PPAR $\gamma$ controls metabolic patterns in neural precursors and shh-driven medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 587-600.	3.9	43
282	The Shh Receptor Boc Promotes Progression of Early Medulloblastoma to Advanced Tumors. <i>Developmental Cell</i> , 2014, 31, 34-47.	3.1	43
283	Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. <i>Oncogene</i> , 2017, 36, 5231-5242.	2.6	43
284	Sellar Region Atypical Teratoid/Rhabdoid Tumors (ATRT) in Adults Display DNA Methylation Profiles of the ATRT-MYC Subgroup. <i>American Journal of Surgical Pathology</i> , 2018, 42, 506-511.	2.1	43
285	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846.	3.9	43
286	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	0.8	43
287	Telomere dysfunction and chromothripsis. <i>International Journal of Cancer</i> , 2016, 138, 2905-2914.	2.3	42
288	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835.	3.9	42

#	ARTICLE	IF	CITATIONS
289	The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants. <i>Oncogene</i> , 2015, 34, 1126-1140.	2.6	41
290	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860.	2.1	40
291	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015, 21, 3750-3758.	3.2	40
292	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	0.8	40
293	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. <i>Brain Pathology</i> , 2016, 26, 199-205.	2.1	39
294	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. <i>Neuro-Oncology</i> , 2017, 19, 1607-1617.	0.6	39
295	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusion-Positive Supratentorial Ependymomas. <i>Cancer Discovery</i> , 2021, 11, 2230-2247.	7.7	39
296	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. <i>Neuropathology</i> , 2015, 35, 538-544.	0.7	38
297	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. <i>Acta Neuropathologica</i> , 2017, 134, 965-967.	3.9	38
298	Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma. <i>Cancer Research</i> , 2020, 80, 5393-5407.	0.4	38
299	The Role of Chromatin Remodeling in Medulloblastoma. <i>Brain Pathology</i> , 2013, 23, 193-199.	2.1	37
300	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	2.4	37
301	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. <i>Acta Neuropathologica</i> , 2018, 136, 339-343.	3.9	37
302	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019, 7, 163.	2.4	37
303	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	5.8	37
304	Loss of Smarcb Proteins Impairs Cerebellar Development. <i>Journal of Neuroscience</i> , 2014, 34, 13486-13491.	1.7	36
305	Whole exome sequencing reveals that the majority of schwannomatosis cases remain unexplained after excluding SMARCB1 and LZTR1 germline variants. <i>Acta Neuropathologica</i> , 2014, 128, 449-452.	3.9	36
306	Voxel-wise radiogenomic mapping of tumor location with key molecular alterations in patients with glioma. <i>Neuro-Oncology</i> , 2018, 20, 1517-1524.	0.6	36

#	ARTICLE	IF	CITATIONS
307	RF_Purify: a novel tool for comprehensive analysis of tumor-purity in methylation array data based on random forest regression. BMC Bioinformatics, 2019, 20, 428.	1.2	36
308	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). Acta Neuropathologica, 2021, 141, 605-617.	3.9	36
309	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. Acta Neuropathologica, 2021, 142, 841-857.	3.9	36
310	Pediatric Gliomas. Recent Results in Cancer Research, 2009, 171, 67-81.	1.8	35
311	Arhgap36-dependent activation of Gli transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11061-11066.	3.3	35
312	Opposing Effects of CREBBP Mutations Govern the Phenotype of Rubinstein-Taybi Syndrome and Adult SHH Medulloblastoma. Developmental Cell, 2018, 44, 709-724.e6.	3.1	35
313	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. Acta Neuropathologica Communications, 2018, 6, 48.	2.4	35
314	The $\beta$ -catenin/CBP-antagonist ICG-001 inhibits pediatric glioma tumorigenicity in a Wnt-independent manner. Oncotarget, 2017, 8, 27300-27313.	0.8	35
315	The Transcription Factor Evi-1 Is Overexpressed, Promotes Proliferation, and Is Prognostically Unfavorable in Infratentorial Ependymomas. Clinical Cancer Research, 2011, 17, 3631-3637.	3.2	34
316	Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. Genes Chromosomes and Cancer, 2016, 55, 418-427.	1.5	34
317	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	3.9	34
318	EGFL7 enhances surface expression of integrin $\alpha 5 \beta 1$ to promote angiogenesis in malignant brain tumors. EMBO Molecular Medicine, 2018, 10, .	3.3	33
319	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
320	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. American Journal of Pathology, 2016, 186, 446-459.	1.9	32
321	Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation in the NCT Neuro Master Match (N2M2) pilot study. Neuro-Oncology, 2018, 20, 826-837.	0.6	32
322	<i>ZFTA</i> Translocations Constitute Ependymoma Chromatin Remodeling and Transcription Factors. Cancer Discovery, 2021, 11, 2216-2229.	7.7	32
323	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. Neuro-Oncology, 2017, 19, 1183-1194.	0.6	31
324	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. Neuro-Oncology, 2019, 21, 214-221.	0.6	31

#	ARTICLE	IF	CITATIONS
325	DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. <i>Neuro-Oncology</i> , 2021, 23, 240-250.	0.6	31
326	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. <i>Acta Neuropathologica</i> , 2021, 141, 281-290.	3.9	31
327	Pseudoprogression in children, adolescents and young adults with non-brainstem high grade glioma and diffuse intrinsic pontine glioma. <i>Journal of Neuro-Oncology</i> , 2016, 129, 109-121.	1.4	30
328	Update on molecular and genetic alterations in adult medulloblastoma. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 228-232.	0.3	29
329	Preliminary experience with personalized and targeted therapy for pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 27-33.	0.8	29
330	<i>PID1</i> ( <i>NYGGF4</i> ), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas. <i>Clinical Cancer Research</i> , 2014, 20, 827-836.	3.2	29
331	No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. <i>Human Genetics</i> , 2016, 135, 469-475.	1.8	29
332	Key Implications of Data Sharing in Pediatric Genomics. <i>JAMA Pediatrics</i> , 2018, 172, 476.	3.3	29
333	Duplications of KIAA1549 and BRAF screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for KIAA1549-BRAF fusion detection in pilocytic astrocytomas. <i>Modern Pathology</i> , 2018, 31, 1490-1501.	2.9	29
334	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 97-104.	1.2	29
335	Critical role of zinc finger protein 521 in the control of growth, clonogenicity and tumorigenic potential of medulloblastoma cells. <i>Oncotarget</i> , 2013, 4, 1280-1292.	0.8	29
336	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , 2021, 13, eabc0497.	5.8	29
337	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 485-499.	3.9	28
338	Identification of genes involved in the biology of atypical teratoid/rhabdoid tumours using <i>Drosophila melanogaster</i> . <i>Nature Communications</i> , 2014, 5, 4005.	5.8	28
339	Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of LIN28A and C19MC. <i>American Journal of Ophthalmology</i> , 2015, 159, 1065-1074.e1.	1.7	28
340	Nestin Mediates Hedgehog Pathway Tumorigenesis. <i>Cancer Research</i> , 2016, 76, 5573-5583.	0.4	28
341	Epidemiology, molecular classification and WHO grading of ependymoma. <i>Journal of Neurosurgical Sciences</i> , 2017, 62, 46-50.	0.3	28
342	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. <i>Modern Pathology</i> , 2021, 34, 1558-1569.	2.9	28

#	ARTICLE	IF	CITATIONS
343	Emergence and maintenance of actionable genetic drivers at medulloblastoma relapse. <i>Neuro-Oncology</i> , 2022, 24, 153-165.	0.6	28
344	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. <i>Acta Neuropathologica</i> , 2011, 122, 787-790.	3.9	27
345	Coagulation and angiogenic gene expression profiles are defined by molecular subgroups of medulloblastoma: evidence for growth factorâ€thrombin crossâ€talk. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1838-1849.	1.9	27
346	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia. <i>Clinical Epigenetics</i> , 2019, 11, 188.	1.8	27
347	Single cell derived mRNA signals across human kidney tumors. <i>Nature Communications</i> , 2021, 12, 3896.	5.8	27
348	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. <i>Oncotarget</i> , 2016, 7, 61860-61873.	0.8	27
349	MRI Radiogenomics of Pediatric Medulloblastoma: A Multicenter Study. <i>Radiology</i> , 2022, 304, 406-416.	3.6	27
350	Neogenin1 is a sonic hedgehog target in medulloblastoma and is necessary for cell cycle progression. <i>International Journal of Cancer</i> , 2014, 134, 21-31.	2.3	26
351	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017, 134, 155-158.	3.9	26
352	Fatal Outcome of European Tick-borne Encephalitis after Vaccine Failure. <i>Frontiers in Neurology</i> , 2017, 8, 119.	1.1	26
353	Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	26
354	Maturation Block in Childhood Cancer. <i>Cancer Discovery</i> , 2021, 11, 542-544.	7.7	25
355	Integrative gene network and functional analyses identify a prognostically relevant key regulator of metastasis in Ewing sarcoma. <i>Molecular Cancer</i> , 2022, 21, 1.	7.9	25
356	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 229-238.	1.5	24
357	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1355-1363.	3.2	24
358	DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas. <i>Neuro-Oncology</i> , 2019, 21, 867-877.	0.6	24
359	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. <i>BMC Cancer</i> , 2020, 20, 523.	1.1	24
360	Second series by the Italian Association of Pediatric Hematology and Oncology of children and adolescents with intracranial ependymoma: an integrated molecular and clinical characterization with a long-term follow-up. <i>Neuro-Oncology</i> , 2021, 23, 848-857.	0.6	24

#	ARTICLE	IF	CITATIONS
361	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	3.9	24
362	Radiation-induced gliomas represent H3-/IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. <i>Nature Communications</i> , 2021, 12, 5530.	5.8	24
363	Accumulation of genomic aberrations during clinical progression of medulloblastoma. <i>Acta Neuropathologica</i> , 2008, 116, 383-390.	3.9	23
364	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 20.	2.4	23
365	Molecular approaches to ependymoma. <i>Current Opinion in Neurology</i> , 2012, 25, 745-750.	1.8	22
366	Oncolytic effects of parvovirus Hâ€œ1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. <i>International Journal of Cancer</i> , 2014, 134, 703-716.	2.3	22
367	Serpine2/PN-1 Is Required for Proliferative Expansion of Pre-Neoplastic Lesions and Malignant Progression to Medulloblastoma. <i>PLoS ONE</i> , 2015, 10, e0124870.	1.1	22
368	Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. <i>Neuro-Oncology</i> , 2021, 23, 226-239.	0.6	22
369	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	0.6	22
370	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. <i>Child's Nervous System</i> , 2011, 27, 1243-1249.	0.6	21
371	Emerging Insights into the Ependymoma Epigenome. <i>Brain Pathology</i> , 2013, 23, 206-209.	2.1	21
372	p19-INK4d inhibits neuroblastoma cell growth, induces differentiation and is hypermethylated and downregulated in MYCN-amplified neuroblastomas. <i>Human Molecular Genetics</i> , 2014, 23, 6826-6837.	1.4	21
373	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26893.	0.8	21
374	Opposing Tumor-Promoting and -Suppressive Functions of Rictor/mTORC2 Signaling in Adult Glioma and Pediatric SHH Medulloblastoma. <i>Cell Reports</i> , 2018, 24, 463-478.e5.	2.9	21
375	Molecular correlates of cerebellar mutism syndrome in medulloblastoma. <i>Neuro-Oncology</i> , 2020, 22, 290-297.	0.6	21
376	Drivers underpinning the malignant transformation of giant cell tumour of bone. <i>Journal of Pathology</i> , 2020, 252, 433-440.	2.1	21
377	Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing. <i>Haematologica</i> , 2017, 102, e179-e183.	1.7	20
378	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). <i>Acta Neuropathologica</i> , 2018, 136, 303-313.	3.9	20

#	ARTICLE	IF	CITATIONS
379	Proteomic profiling of high risk medulloblastoma reveals functional biology. <i>Oncotarget</i> , 2015, 6, 14584-14595.	0.8	20
380	An essential role for p38 MAPK in cerebellar granule neuron precursor proliferation. <i>Acta Neuropathologica</i> , 2012, 123, 573-586.	3.9	19
381	Molecular dissection of ependymomas. <i>Oncoscience</i> , 2015, 2, 827-828.	0.9	19
382	Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 603-607.	1.4	19
383	Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. <i>Oncologist</i> , 2019, 24, e921-e929.	1.9	19
384	Local and systemic therapy of recurrent ependymoma in children and adolescents: short- and long-term results of the E-HIT-REZ 2005 study. <i>Neuro-Oncology</i> , 2021, 23, 1012-1023.	0.6	19
385	Rapid-CNS2: rapid comprehensive adaptive nanopore-sequencing of CNS tumors, a proof-of-concept study. <i>Acta Neuropathologica</i> , 2022, 143, 609-612.	3.9	19
386	Epigenetic Silencing of DKK3 in Medulloblastoma. <i>International Journal of Molecular Sciences</i> , 2013, 14, 7492-7505.	1.8	18
387	Translating genomic medicine to the clinic: challenges and opportunities. <i>Genome Medicine</i> , 2019, 11, 9.	3.6	18
388	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018, 135, 635-638.	3.9	17
389	FOXR2 Stabilizes MYCN Protein and Identifies Non- <i>MYCN</i> -Amplified Neuroblastoma Patients With Unfavorable Outcome. <i>Journal of Clinical Oncology</i> , 2021, 39, 3217-3228.	0.8	17
390	Intimal sarcomas and undifferentiated cardiac sarcomas carry mutually exclusive MDM2, MDM4, and CDK6 amplifications and share a common DNA methylation signature. <i>Modern Pathology</i> , 2021, 34, 2122-2129.	2.9	17
391	EZH1P: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma. <i>Acta Neuropathologica</i> , 2022, 143, 1-13.	3.9	17
392	Prognostic relevance of miR-124-3p and its target <i>TP53INP1</i> in pediatric ependymoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 639-650.	1.5	16
393	Biological material collection to advance translational research and treatment of children with CNS tumours: position paper from the SIOPE Brain Tumour Group. <i>Lancet Oncology</i> , The, 2018, 19, e419-e428.	5.1	16
394	Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation. <i>Genes and Development</i> , 2020, 34, 1161-1176.	2.7	16
395	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	3.9	16
396	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. <i>Nature Communications</i> , 2022, 13, .	5.8	16

#	ARTICLE	IF	CITATIONS
397	SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature. <i>Child's Nervous System</i> , 2016, 32, 2439-2446.	0.6	15
398	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. <i>PLoS ONE</i> , 2017, 12, e0178351.	1.1	15
399	<i>BRAF</i> V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2018, 36, 96-96.	0.8	15
400	From Sampling to Sequencing: A Liquid Biopsy Pre-Analytic Workflow to Maximize Multi-Layer Genomic Information from a Single Tube. <i>Cancers</i> , 2021, 13, 3002.	1.7	15
401	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	2.1	14
402	InTAD: chromosome conformation guided analysis of enhancer target genes. <i>BMC Bioinformatics</i> , 2019, 20, 60.	1.2	14
403	Rapid and Sensitive Quantification of Osimertinib in Human Plasma Using a Fully Validated MALDI-IMS/MS Assay. <i>Cancers</i> , 2020, 12, 1897.	1.7	14
404	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1462-1468.	1.9	14
405	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. <i>Oncotarget</i> , 2015, 6, 31844-31856.	0.8	14
406	Primary central nervous system sarcoma with <i>DICER1</i> mutation—treatment results of a novel molecular entity in pediatric Peruvian patients. <i>Cancer</i> , 2022, 128, 697-707.	2.0	14
407	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 558-568.	1.5	13
408	DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis. <i>Journal of Neuro-Oncology</i> , 2012, 109, 415-423.	1.4	13
409	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with <i>VSNL1</i> as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	3.9	13
410	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. <i>Advances in Radiation Oncology</i> , 2020, 5, 1158-1169.	0.6	13
411	Rapid and Sensitive Drug Quantification in Tissue Sections Using Matrix Assisted Laser Desorption Ionization-Ion Mobility-Mass Spectrometry Profiling. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 742-751.	1.2	13
412	A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in <i>BRAF</i> -Driven Pediatric Low-Grade Glioma Cells. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1736-1750.	1.9	13
413	Gain of 12p encompassing <i>CCND2</i> is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327.	3.9	12
414	Accurate calling of <i>KIAA1549-BRAF</i> fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414.	1.8	12



#	ARTICLE	IF	CITATIONS
415	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , 2021, 142, 873-886.	3.9	12
416	The pediatric precision oncology study INFORM: Clinical outcome and benefit for molecular subgroups. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA10503-LBA10503.	0.8	12
417	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	2.4	12
418	Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis. <i>Cancer Research</i> , 2003, 63, 1772-5.	0.4	12
419	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment. <i>Cancers</i> , 2022, 14, 126.	1.7	12
420	Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 511-514.	0.3	11
421	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	3.9	11
422	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1796-1803.	1.2	11
423	EORTC SPECTRA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe. <i>International Journal of Cancer</i> , 2020, 147, 1180-1184.	2.3	11
424	Rapid MALDI-MS Assays for Drug Quantification in Biological Matrices: Lessons Learned, New Developments, and Future Perspectives. <i>Molecules</i> , 2021, 26, 1281.	1.7	11
425	Spatial Dissection of Invasive Front from Tumor Mass Enables Discovery of Novel microRNA Drivers of Glioblastoma Invasion. <i>Advanced Science</i> , 2021, 8, e2101923.	5.6	11
426	Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies. <i>European Journal of Cancer</i> , 2022, 162, 107-117.	1.3	11
427	Connect Four with Glioblastoma Stem Cell Factors. <i>Cell</i> , 2014, 157, 525-527.	13.5	10
428	Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples. <i>Journal of Clinical Virology</i> , 2015, 69, 33-35.	1.6	10
429	Molecular tumor classification using DNA methylome analysis. <i>Human Molecular Genetics</i> , 2020, 29, R205-R213.	1.4	10
430	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. <i>Neuro-Oncology</i> , 2020, 22, 1327-1338.	0.6	10
431	MEK and RAF inhibitors: time for a paradigm shift in the treatment of pediatric low-grade gliomas?. <i>Neuro-Oncology</i> , 2017, 19, 741-743.	0.6	9
432	Systematic identification of suspected anthelmintic benzimidazole metabolites using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 151, 151-158.	1.4	9

#	ARTICLE	IF	CITATIONS
433	Imaging Characteristics of Wingless Pathway Subgroup Medulloblastomas: Results from the German HIT/SIOP-Trial Cohort. <i>American Journal of Neuroradiology</i> , 2019, 40, 1811-1817.	1.2	9
434	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015.	3.9	9
435	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. <i>Acta Neuropathologica</i> , 2020, 139, 403-406.	3.9	9
436	Notch Signaling between Cerebellar Granule Cell Progenitors. <i>ENeuro</i> , 2021, 8, ENEURO.0468-20.2021.	0.9	9
437	Treatment of embryonal tumors with multilayered rosettes with carboplatin/etoposide induction and high-dose chemotherapy within the prospective P-HIT trial. <i>Neuro-Oncology</i> , 2022, 24, 127-137.	0.6	9
438	TP53 codon 72 polymorphism may predict early tumour progression in paediatric pilocytic astrocytoma. <i>Oncotarget</i> , 2016, 7, 47918-47926.	0.8	9
439	Local and Systemic Therapy of Recurrent Medulloblastomas in Children and Adolescents: Results of the P-HIT-REZ 2005 Study. <i>Cancers</i> , 2022, 14, 471.	1.7	9
440	Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation. <i>Acta Neuropathologica</i> , 2011, 121, 283-285.	3.9	8
441	Molecular Diagnostics in Pediatric Brain Tumors: Impact on Diagnosis and Clinical Decision-Making – A Selected Case Series. <i>Klinische Padiatrie</i> , 2018, 230, 305-313.	0.2	8
442	Downregulation of miR-326 and its host gene <i>p19<sup>Arrestin1</sup></i> induces pro-survival activity of E2F1 and promotes medulloblastoma growth. <i>Molecular Oncology</i> , 2021, 15, 523-542.	2.1	8
443	An extracellular vesicle-related gene expression signature identifies high-risk patients in medulloblastoma. <i>Neuro-Oncology</i> , 2021, 23, 586-598.	0.6	8
444	Development of Randomized Trials in Adults with Medulloblastoma – The Example of EORTC 1634-BTG/NOA-23. <i>Cancers</i> , 2021, 13, 3451.	1.7	8
445	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 116-128.	3.2	8
446	From glioblastoma to gangliocytoma: an unforeseen but welcome shift in biological behavior. <i>Journal of Neurosurgery: Pediatrics</i> , 2009, 4, 475-478.	0.8	7
447	Simple Estimation of Incident HIV Infection Rates in Notification Cohorts Based on Window Periods of Algorithms for Evaluation of Line-Immunoassay Result Patterns. <i>PLoS ONE</i> , 2013, 8, e71662.	1.1	7
448	SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors. <i>Journal of Neuro-Oncology</i> , 2017, 131, 477-484.	1.4	7
449	Two molecularly distinct atypical teratoid/rhabdoid tumors (or tumor components) occurring in an infant with rhabdoid tumor predisposition syndrome 1. <i>Acta Neuropathologica</i> , 2019, 137, 847-850.	3.9	7
450	Genome-wide analysis of acute leukemia and clonally related histiocytic sarcoma in a series of three pediatric patients. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28074.	0.8	7

#	ARTICLE	IF	CITATIONS
451	Systematic target actionability reviews of preclinical proof-of-concept papers to match targeted drugs to paediatric cancers. <i>European Journal of Cancer</i> , 2020, 130, 168-181.	1.3	7
452	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585.	0.6	7
453	Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model. <i>Neuro-Oncology</i> , 2021, 23, 2028-2041.	0.6	7
454	Limitations of current <i>in vitro</i> models for testing the clinical potential of epigenetic inhibitors for treatment of pediatric ependymoma. <i>Oncotarget</i> , 2018, 9, 36530-36541.	0.8	7
455	Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043.	3.9	7
456	The age of adult pilocytic astrocytoma cells. <i>Oncogene</i> , 2021, 40, 2830-2841.	2.6	6
457	High-Resolution Cartography of the Transcriptome and Methylome Landscapes of Diffuse Gliomas. <i>Cancers</i> , 2021, 13, 3198.	1.7	6
458	Notch1 switches progenitor competence in inducing medulloblastoma. <i>Science Advances</i> , 2021, 7, .	4.7	6
459	Abstract 4347: Medulloblastoma comprises four distinct diseases. , 2010, , .		6
460	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies. <i>Journal of Neuro-Oncology</i> , 2021, 155, 193-202.	1.4	6
461	Analytical Performance Evaluation of New DESI Enhancements for Targeted Drug Quantification in Tissue Sections. <i>Pharmaceuticals</i> , 2022, 15, 694.	1.7	6
462	GE-23 * ENHANCER HIJACKING ACTIVATES GF11 FAMILY ONCOGENES IN MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2014, 16, v101-v101.	0.6	5
463	Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. <i>PLoS ONE</i> , 2019, 14, e0210665.	1.1	5
464	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. <i>Acta Neuropathologica</i> , 2020, 140, 237-239.	3.9	5
465	INFORM2 exploratory multinational phase I/II combination study of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies: INFORM2 NivEnt.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS10065-TPS10065.	0.8	5
466	Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. <i>Acta Neuropathologica</i> , 2022, 144, 339-352.	3.9	5
467	BI-30 * CHARACTERIZATION OF L1CAM AS A CLINICAL MARKER FOR THE C11orf95-RELA FUSION IN SUPRATENTORIAL EPENDYMOMAS. <i>Neuro-Oncology</i> , 2014, 16, v30-v30.	0.6	4
468	<i>P</i> -aired box gene 8 ( <i>PAX8</i> ) expression is associated with sonic hedgehog ( <i>SHH</i> )/wingless int ( <i>WNT</i> ) subtypes, desmoplastic histology and patient survival in human medulloblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 165-179.	1.8	4

#	ARTICLE	IF	CITATIONS
469	Cancer predisposition in pediatric neuro-oncology – practical approaches and ethical considerations. <i>Neuro-Oncology Practice</i> , 2021, 8, 526-538.	1.0	4
470	Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation Neuro Master Match (N <sup>2</sup> M <sup>2</sup> ).. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS2084-TPS2084.	0.8	4
471	Pediatric T-ALL type-1 and type-2 relapses develop along distinct pathways of clonal evolution. <i>Leukemia</i> , 2022, 36, 1759-1768.	3.3	4
472	Target actionability review to evaluate CDK4/6 as a therapeutic target in paediatric solid and brain tumours. <i>European Journal of Cancer</i> , 2022, 170, 196-208.	1.3	4
473	Cancer risk and tumour spectrum in 172 patients with a germline <i>SUFU</i> pathogenic variation: a collaborative study of the SIOPE Host Genome Working Group. <i>Journal of Medical Genetics</i> , 2022, 59, 1123-1132.	1.5	4
474	Medulloepithelioma with peculiar clinical presentation, stem cell phenotype and aberrant DNA-methylation profile. <i>CNS Oncology</i> , 2015, 4, 203-212.	1.2	3
475	LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B. <i>Neuro-Oncology</i> , 2019, 21, ii98-ii99.	0.6	3
476	Investigating the Central Nervous System Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. <i>Pharmaceutics</i> , 2021, 13, 1498.	2.0	3
477	The genomic landscape of pediatric renal cell carcinomas. <i>IScience</i> , 2022, 25, 104167.	1.9	3
478	SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1277-1283.	2.1	3
479	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e348-e349.	0.8	2
480	Medulloblastoma: a potpourri of distinct entities. <i>Acta Neuropathologica</i> , 2012, 123, 463-464.	3.9	2
481	Integrative Genomic Analyses of Atypical Teratoid Rhabdoid Tumours (ATRTs). <i>Cancer Genetics</i> , 2014, 207, 447-448.	0.2	2
482	Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities. <i>Public Health Genomics</i> , 2016, 19, 170-177.	0.6	2
483	EPEN-06. YAP1 SUBGROUP SUPRATENTORIAL EPENDYMOMA REQUIRES TEAD AND NUCLEAR FACTOR I-MEDIATED TRANSCRIPTIONAL PROGRAMS FOR TUMORIGENESIS. <i>Neuro-Oncology</i> , 2019, 21, ii78-ii78.	0.6	2
484	GENE-08. THE MNP 2.0 STUDY: PROSPECTIVE INTEGRATION OF DNA METHYLATION PROFILING IN CNS TUMOR DIAGNOSTICS. <i>Neuro-Oncology</i> , 2019, 21, ii82-ii82.	0.6	2
485	Molecular progression of SHH-activated medulloblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 327-330.	3.9	2
486	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab002.	0.4	2

#	ARTICLE	IF	CITATIONS
487	ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab030.	0.4	2
488	<i>NTRK</i> Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. <i>JCO Precision Oncology</i> , 2021, 5, 450-454.	1.5	2
489	Bioanalysis of selinexor in mouse plasma micro-samples utilizing UPLC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1176, 122781.	1.2	2
490	A systematic analysis of genetic interactions and their underlying biology in childhood cancer. <i>Communications Biology</i> , 2021, 4, 1139.	2.0	2
491	Important Requirements for the Selection of Internal Standards during the Development of Desorption/Ionization Assays for Drug Quantification in Biological Matrices—A Practical Example. <i>Molecules</i> , 2022, 27, 690.	1.7	2
492	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. <i>Journal of Neuro-Oncology</i> , 2022, 157, 37-48.	1.4	2
493	MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression. <i>Biomarker Research</i> , 2022, 10, .	2.8	2
494	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. <i>BMC Proceedings</i> , 2012, 6, .	1.8	1
495	Revealing the role of SGK1 in the dynamics of medulloblastoma using a mathematical model. <i>Journal of Theoretical Biology</i> , 2014, 354, 105-112.	0.8	1
496	Next-generation molecular diagnostics. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 121-130.	1.0	1
497	Interrogating the enhancer landscape of intracranial ependymomas: perspectives for precision medicine. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 147-149.	0.4	1
498	PDTM-38. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi212-vi212.	0.6	1
499	CRISPR-mediated Loss of Function Analysis in Cerebellar Granule Cells Using <em>In Utero</em> Electroporation-based Gene Transfer. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	1
500	MEDU-01. HDACi AND PLK1i ACT SYNERGISTICALLY IN MYC-AMPLIFIED MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, ii103-ii103.	0.6	1
501	Probing Medulloblastoma Initiation at the Single-Cell Level. <i>Trends in Cancer</i> , 2019, 5, 759-761.	3.8	1
502	GENE-12. ANAPLASTIC NEUROEPITHELIAL TUMOR WITH CONDENSED NUCLEI (ANTCON): A NOVEL BRAIN TUMOR ENTITY WITH RECURRENT NTRK FUSION. <i>Neuro-Oncology</i> , 2019, 21, ii83-ii83.	0.6	1
503	EPEN-03. ZFTA/C11ORF95 FUSIONS DRIVE SUPRATENTORIAL EPENDYMOMA VIA SHARED ONCOGENIC MECHANISMS. <i>Neuro-Oncology</i> , 2021, 23, i13-i14.	0.6	1
504	ETMR-03. THE ROLE OF FOXR2 IN PEDIATRIC BRAIN CANCER. <i>Neuro-Oncology</i> , 2020, 22, iii323-iii323.	0.6	1

#	ARTICLE	IF	CITATIONS
505	Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network.. Journal of Clinical Oncology, 2017, 35, 2038-2038.	0.8	1
506	EPEN-39. CLINICAL STRATIFIED TREATMENT OF LOCALIZED PEDIATRIC INTRACRANIAL EPENDYMOMA WITH COMBINED LOCAL IRRADIATION AND CHEMOTHERAPY WITHIN THE PROSPECTIVE, MULTICENTER E-HIT TRIAL â€œ THE MOLECULAR SUBGROUP MATTERS. Neuro-Oncology, 2020, 22, iii315-iii316.	0.6	1
507	Predictive modeling of resistance to SMO-inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma. Neuro-Oncology Advances, 2022, 4, vdac026.	0.4	1
508	MEDB-14. Clinical outcome of pediatric medulloblastoma patients with Li-Fraumeni syndrome. Neuro-Oncology, 2022, 24, i107-i107.	0.6	1
509	LGG-14. LOGGIC (Low Grade Glioma in Children) Core BioClinical Data Bank: Establishment and added clinical value of an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro-Oncology, 2022, 24, i90-i90.	0.6	1
510	MEDB-04. Young children with metastatic medulloblastoma: frequent requirement for radiotherapy in children with non-WNT/non-SHH medulloblastoma despite highly intensified chemotherapy â€œ Results of the MET-HIT2000-BIS4 trial. Neuro-Oncology, 2022, 24, i104-i104.	0.6	1
511	RARE-15. Astroblastoma, <i>MN1</i> altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners <i>BEND2</i> and <i>CXXC5</i>. Neuro-Oncology, 2022, 24, i12-i13.	0.6	1
512	EPIGENOME ALTERATIONS DEFINE LETHAL CIMP POSITIVE EPENDYMOMAS OF INFANCY. Neuro-Oncology, 2014, 16, iii16-iii16.	0.6	0
513	GE-21 * DRASTIC GENOMIC DIVERGENCE OF RECURRENT MEDULLOBLASTOMA INVALIDATES TARGETED THERAPIES DISCOVERED AT DIAGNOSIS. Neuro-Oncology, 2014, 16, v100-v101.	0.6	0
514	EG-09 * EPIGENETIC PROFILING REVEALS A CpG HYPERMETHYLATION PHENOTYPE (CIMP) ASSOCIATED WITH WORSE PROGRESSION-FREE SURVIVAL IN MENINGIOMA. Neuro-Oncology, 2014, 16, v76-v77.	0.6	0
515	Guanine Nucleotide-Binding Protein Î± Subunit Hypofunction in Children with Short Stature and Disproportionate Shortening of the 4th and 5th Metacarpals. Hormone Research in Paediatrics, 2014, 81, 196-203.	0.8	0
516	MPTH-26 MOLECULAR REFINEMENT OF PEDIATRIC POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2015, 17, v144.1-v144.	0.6	0
517	Ependymoma. Molecular Pathology Library, 2015, , 67-75.	0.1	0
518	HG-68 COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2016, 18, iii63.2-iii63.	0.6	0
519	ATRT-24. CHROMATIN SEGMENTATION IN ATRT REVEALS AN IMPORTANT ROLE FOR RESIDUAL SWI/SNF MEMBERS. Neuro-Oncology, 2018, 20, i33-i33.	0.6	0
520	LGG-11. REGULATION OF ONCOGENE-INDUCED SENESCENCE IN PILOCYTIC ASTROCYTOMA. Neuro-Oncology, 2018, 20, i106-i106.	0.6	0
521	MBRS-12. INTERFERENCE WITH THE FUNCTION OF MYC IN GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2018, 20, i130-i130.	0.6	0
522	MBCL-45. ROLE OF IRRADIATION IN RELAPSED MEDULLOBLASTOMA: A REPORT OF THE GERMAN MEDULLOBLASTOMA RELAPSE STUDIES. Neuro-Oncology, 2018, 20, i127-i127.	0.6	0

#	ARTICLE	IF	CITATIONS
523	Modern Principles of CNS Tumor Classification. , 2018, , 117-129.		0
524	EPEN-07. OVEREXPRESSION AND MUTATIONS OF CXORF67 IN â€˜INFANT-TYPEâ€™ POSTERIOR FOSSA TYPE-A (PFA) EPENDYMOMAS. Neuro-Oncology, 2018, 20, i74-i74.	0.6	0
525	ATRT-34. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology, 2018, 20, i35-i35.	0.6	0
526	A Mouse Ependymoma Model Provides Molecular Insights into Tumor Formation. Cell Reports, 2018, 23, 3699-3700.	2.9	0
527	MEDU-11. MOLECULAR CHARACTERIZATION OF ETMRs REVEALS A ROLE FOR R-LOOP MEDIATED CHROMOSOMAL INSTABILITY. Neuro-Oncology, 2019, 21, ii105-ii105.	0.6	0
528	GENE-13. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. Neuro-Oncology, 2019, 21, ii83-ii84.	0.6	0
529	ATRT-09. INTEGRATIVE ANALYSES OF GENE REGULATORY LANDSCAPES REVEAL RHABDOID TUMOR SUBGROUPS WITH POSSIBLE IMMUNE MODULATION THROUGH EPIGENETIC DYSREGULATION. Neuro-Oncology, 2019, 21, ii64-ii65.	0.6	0
530	Reply to â€˜Assembling the brain trust: the multidisciplinary imperative in neuro-oncologyâ€™. Nature Reviews Clinical Oncology, 2019, 16, 522-523.	12.5	0
531	ATRT-07. TARGETING PRIMARY CILIOGENESIS IN ATYPICAL TERATOID/RHABDOID TUMORS. Neuro-Oncology, 2019, 21, ii64-ii64.	0.6	0
532	EPEN-04. CXorf67 MIMICS ONCOGENIC HISTONE H3 K27M MUTATIONS AND FUNCTIONS AS INTRINSIC INHIBITOR OF PRC2 FUNCTION IN AGGRESSIVE POSTERIOR FOSSA EPENDYMOMA. Neuro-Oncology, 2019, 21, ii78-ii78.	0.6	0
533	GENE-02. CHROMOSOME CONFORMATION ANALYSIS OF EPENDYMOMA IDENTIFIES PUTATIVE TUMOR DEPENDENCY GENES ACTIVATED BY DISTAL ONCOGENIC ENHANCERS. Neuro-Oncology, 2019, 21, ii80-ii81.	0.6	0
534	GENE-04. ESTABLISHING A MOLECULAR PROFILING SERVICE FOR CHILDRENâ€™S CENTRAL NERVOUS SYSTEM TUMORS IN AUSTRALASIA â€˜ THE AUSTRALIAN AND NEW ZEALAND CHILDRENâ€™S HAEMATOLOGY AND ONCOLOGY GROUP (ANZCHOG) AIM BRAIN PROJECT. Neuro-Oncology, 2019, 21, ii81-ii81.	0.6	0
535	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. Neuro-Oncology, 2019, 21, ii81-ii82.	0.6	0
536	LGG-13. PAPILLARY GLIONEURONAL TUMOR (PGNT) EXHIBITS A CHARACTERISTIC METHYLATION PROFILE AND MANDATORY FUSIONS INVOLVING PRKCA. Neuro-Oncology, 2019, 21, ii101-ii102.	0.6	0
537	MEDU-21. LOSS OF THE TRANSCRIPTIONAL CO-REPRESSOR BCOR LEADS TO OVEREXPRESSION OF THE GROWTH FACTOR IGF2 AND SHH MEDULLOBLASTOMA TUMOR FORMATION. Neuro-Oncology, 2019, 21, ii107-ii108.	0.6	0
538	Advances and Challenges in Pediatric and Childhood Cancers. Cancer Cell, 2020, 38, 429-432.	7.7	0
539	EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i5-i5.	0.6	0
540	EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY. Neuro-Oncology, 2021, 23, i10-i10.	0.6	0

#	ARTICLE	IF	CITATIONS
541	IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2021, 23, i30-i30.	0.6	0
542	LGG-04. MULTIOMIC ANALYSIS OF MAPK PATHWAY ACTIVITY IN PEDIATRIC PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2021, 23, i31-i32.	0.6	0
543	TMOD-03. A NOVEL MB GR3 TRANSGENIC MOUSE MODEL IS GENERATED BY <i>MYCN</i> AND <i>P53</i> DEFECTS IN VENTRICULAR ZONE PROGENITORS.. <i>Neuro-Oncology</i> , 2021, 23, i36-i36.	0.6	0
544	LGG-06. COMPREHENSIVE GENOMIC CHARACTERIZATION AND INTEGRATED CLINICAL ANALYSIS OF LOW-GRADE GLIOMAS IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2021, 23, i32-i32.	0.6	0
545	EPCT-06. PRECISION ONCOLOGY IN THE PEDIATRIC TARGETED THERAPY 2.0 PROGRAM. <i>Neuro-Oncology</i> , 2021, 23, i47-i48.	0.6	0
546	LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2021, 23, i33-i34.	0.6	0
547	The Early Treatment Response of the Clinically Challenging Group of Childhood T-ALL without NOTCH1 Mutations Is Signified by a Specific mRNA Gene Profile.. <i>Blood</i> , 2007, 110, 2789-2789.	0.6	0
548	Secretion of Angiogenic Proteins by Human Multipotent Mesenchymal Stromal Cells (MSC) under Hypoxic Culture Conditions and Clinical Application of MSC in Steroid Induced Osteonecrosis in Children.. <i>Blood</i> , 2007, 110, 3689-3689.	0.6	0
549	High-Resolution Genomic Profiling (array-CGH) of Childhood T-ALL Identifies Deletions at 6q15-16.1 as a Predictive Marker for Early Treatment Response.. <i>Blood</i> , 2008, 112, 1484-1484.	0.6	0
550	Progressively Metastasizing Ependymoma: Genomic Aberrations. , 2012, , 297-306.		0
551	Abstract 1313: Mutually exclusive somatic mutations in WNT pathway medulloblastomas reveal a critical interaction between DDX3X and SMARCA4. , 2012, , .		0
552	Abstract LB-198: Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. , 2014, , .		0
553	Abstract 3089: (Epi)genetic profiling enables molecular re-classification of CNS-primitive neuroectodermal tumors. , 2014, , .		0
554	Abstract 3094: Epigenetic classification of ependymal brain tumors across age groups. , 2014, , .		0
555	Abstract 2891: Landscape of infiltrating immune repertoire in pediatric solid tumors. , 2019, , .		0
556	Abstract 3646: (Epi-)genomic homogeneity in radiation-induced glioblastoma with recurrentPDGFRAamplification and loss ofCDKN2A/Bfollowing primary acute lymphatic leukemia and medulloblastoma. , 2019, , .		0
557	Abstract 3660: A link between miRNAs and mRNA translation elongation: The let7-eEF2K axis in MYC-driven pediatric tumors adaptation to nutrient deprivation. , 2019, , .		0
558	Abstract SY09-01: A comprehensive European approach to precision pediatric cancer medicine. , 2020, , .		0



#	ARTICLE	IF	CITATIONS
559	EPEN-09. IMPACT OF MOLECULAR SUBGROUP ON OUTCOME FOR INFANTS &lt;lt;12 MONTHS WITH INTRACRANIAL EPENDYMOMA - GERMAN EXPERIENCE FROM HIT2000, INTERIM-2000-REGISTRY AND I-HIT-MED REGISTRY. <i>Neuro-Oncology</i> , 2020, 22, iii309-iii309.	0.6	0
560	QOL-13. NEUROCOGNITIVE OUTCOMES ACCORDING TO RISK-ADAPTED TREATMENT REGIMENS FOR CHILDREN OLDER THAN 4 WITH MEDULLOBLASTOMA AND POSTERIOR FOSSA EPENDYMOMA “ RESULTS OF THE HIT2000 TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii433-iii433.	0.6	0
561	EPEN-36. THE TREATMENT OUTCOME OF PAEDIATRIC SUPRATENTORIAL C11ORF95-RELA FUSED EPENDYMOMA: A COMBINED REPORT FROM E-HIT SERIES AND AUSTRALIAN NEW ZEALAND CHILDREN“S HAEMATOLOGY/ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii315-iii315.	0.6	0
562	MBCL-11. TIME TO RADIOTHERAPY IMPACTS SURVIVAL IN PEDIATRIC AND ADOLESCENT NON-METASTATIC MEDULLOBLASTOMA TREATED BY UPFRONT RADIOTHERAPY “ A REPORT FROM THE HIT 2000 TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii389-iii390.	0.6	0
563	HGG-56. EXTENSIVE MOLECULAR HETEROGENEITY WITHIN H3-/IDH-WILDTYPE PEDIATRIC GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii354-iii354.	0.6	0
564	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii327.	0.6	0
565	EPEN-18. CROSS-SPECIES GENOMICS IDENTIFIES GLI2 AS AN ONCOGENE OF C11orf95 FUSION-POSITIVE SUPRATENTORIAL EPENDYMOMA. <i>Neuro-Oncology</i> , 2020, 22, iii311-iii311.	0.6	0
566	EPEN-44. EXTRACELLULAR VESICLES OF SUPRATENTORIAL EPENDYMOMA RELA MEDIATE INTERACTIONS WITH CELLS OF THE TUMOR MICROENVIRONMENT. <i>Neuro-Oncology</i> , 2020, 22, iii316-iii317.	0.6	0
567	MBRS-68. SINGLE NUCLEUS RNA-SEQUENCING DECIPHERS INTRATUMORAL HETEROGENEITY IN MEDULLOBLASTOMA WITH EXTENSIVE NODULARITY (MBEN). <i>Neuro-Oncology</i> , 2020, 22, iii410-iii410.	0.6	0
568	PÄdiatrische Onkologie: Medical need “ Medikamente f¼r krebskranke Kinder. , 0, , .		0
569	Abstract 3496: Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. , 2019, , .		0
570	MODL-02. A novel<i>Cre</i>-conditional<i>cMYC</i>-driven MB Group 3 transgenic mouse model shows traceable leptomeningeal dissemination.. <i>Neuro-Oncology</i> , 2022, 24, i168-i168.	0.6	0
571	RARE-12. Pineoblastoma of children and young adults in a national population: An analysis of the HIT-MED study cohort. <i>Neuro-Oncology</i> , 2022, 24, i11-i12.	0.6	0
572	HGG-50. Specific sensitivity of pediatric high-grade glioma with ATRX inactivation to PARP inhibitor combinations. <i>Neuro-Oncology</i> , 2022, 24, i73-i73.	0.6	0
573	PATH-08. DNA methylation profiling improves routine diagnostics of paediatric CNS tumours: a prospective population-based study. <i>Neuro-Oncology</i> , 2022, 24, i159-i160.	0.6	0
574	HGG-27. Understanding the role of PLAG family transcription factors in cortex development and tumorigenesis. <i>Neuro-Oncology</i> , 2022, 24, i66-i66.	0.6	0
575	MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) and<i>in vivo</i> validation. <i>Neuro-Oncology</i> , 2022, 24, i168-i169.	0.6	0
576	MEDB-60. Medulloblastoma with extensive nodularity mimics cerebellar development and differentiates along the granular precursor lineage. <i>Neuro-Oncology</i> , 2022, 24, i120-i120.	0.6	0

#	ARTICLE	IF	CITATIONS
577	MEDB-38. Significance of CSF cytology and neurologic deterioration in relapsed medulloblastomas in the German HIT-REZ-97/2005 Studies and the HIT-REZ-Register. <i>Neuro-Oncology</i> , 2022, 24, i113-i114.	0.6	0
578	OTHR-32. The Pediatric Targeted Therapy 2.0 registry: robust molecular diagnostics for precision oncology. <i>Neuro-Oncology</i> , 2022, 24, i154-i154.	0.6	0
579	PATH-13. Methylation analysis in the diagnosis of pediatric CNS tumors; a single center experience. <i>Neuro-Oncology</i> , 2022, 24, i161-i161.	0.6	0
580	MEDB-41. Identifying a subgroup of patients with early childhood sonic hedgehog-activated medulloblastoma with unfavorable prognosis after treatment with radiation-sparing regimens including intraventricular methotrexate. <i>Neuro-Oncology</i> , 2022, 24, i114-i115.	0.6	0
581	PATH-03. Clinically Tractable Outcome Prediction of Group 3/4 Medulloblastoma Based on TPD52 Immunohistochemistry: a Multicohort Study. <i>Neuro-Oncology</i> , 2022, 24, i158-i158.	0.6	0
582	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62.	0.6	0
583	MEDB-36. Clinical and molecular heterogeneity within <i>MYC</i> and <i>MYCN</i> amplified medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i113-i113.	0.6	0
584	MEDB-15. Dynamic chromatin alteration induces oncogenic hijacking by essential transcriptional factors during SHH medulloblastoma tumorigenesis. <i>Neuro-Oncology</i> , 2022, 24, i107-i108.	0.6	0
585	MODL-07. DNA methylation-based biobank of murine models for pediatric tumors. <i>Neuro-Oncology</i> , 2022, 24, i169-i170.	0.6	0
586	EPEN-28. Oncogenic dependency of pediatric ependymomas on extracellular vesicle pathways. <i>Neuro-Oncology</i> , 2022, 24, i45-i45.	0.6	0
587	IMMU-04. Transcriptional analysis reveals distinct microenvironmental subgroups across pediatric nervous system tumors. <i>Neuro-Oncology</i> , 2022, 24, i81-i81.	0.6	0
588	HGG-61. Landscape of cancer predisposition in pediatric high-grade glioma. <i>Neuro-Oncology</i> , 2022, 24, i76-i76.	0.6	0
589	EPEN-09. Multi-omics characterization of the blood-brain barrier in molecular groups of ependymoma. <i>Neuro-Oncology</i> , 2022, 24, i40-i40.	0.6	0
590	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. <i>Neuro-Oncology</i> , 2022, 24, i21-i22.	0.6	0
591	PATH-11. Detection of genetic and epigenetic alterations in Liquid Biopsies from pediatric brain tumor patients. <i>Neuro-Oncology</i> , 2022, 24, i160-i161.	0.6	0
592	THER-01. Precision brain tumor therapy by AAV-mediated oncogene editing. <i>Neuro-Oncology</i> , 2022, 24, i185-i186.	0.6	0
593	MODL-01. Targeting replication stress in pediatric brain tumors. <i>Neuro-Oncology</i> , 2022, 24, i168-i168.	0.6	0
594	Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2052-2052.	0.8	0